循环肿瘤DNA
医学
化疗
肿瘤科
内科学
价值(数学)
危险分层
肺癌
残余物
循环肿瘤细胞
微小残留病
癌症研究
DNA
肺
预测值
癌症
临床试验
剩余风险
生物
产量(工程)
化疗方案
细胞
完全响应
免疫学
细胞毒性
作者
Abhishek Ajay,Reza Ferdousi,Peronne L. Joseph,Seren Durer,Ali Rezvani,Zhengyi Chen,Gary M. Wildey,Minh Lam,Pingfu Fu,Afshin Dowlati
摘要
PURPOSE Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy associated with an exceptionally poor prognosis. A limitation in its standard-of-care management is the absence of practical molecular tools for monitoring disease progression. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker with potential applications in prognostication, early detection of cancer recurrence, refined evaluation of treatment response, and improved disease surveillance. MATERIALS AND METHODS We analyzed serial plasma samples from 81 patients with SCLC using a 105-gene hybrid capture-based next-generation sequencing liquid biopsy assay at three key time points: diagnosis, postchemotherapy, and clinical relapse. RESULTS Extensive-stage (ES) patients demonstrated significantly higher median baseline maximum variant allele frequency (VAF max ) compared with limited-stage cases. Notably, limited-stage patients with VAF max >40% experienced outcomes similar to those with ES disease. Across the cohort, median VAF max values declined from 53.30% at baseline to 0.15% during remission and then rose to 38.65% at relapse, reflecting initial therapeutic sensitivity followed by disease recurrence that remained unremitting. Baseline VAF max correlated with the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Moreover, disease-free survival (DFS), defined as the time to relapse from the date of clinical response (evaluated post–4-cycle chemotherapy), was significantly associated with baseline VAF max and a decline in VAF max of <99.89% at remission. Relapse genomic profiles largely mirrored baseline alterations, although some patients showed novel mutations. CONCLUSION Median ctDNA VAF max was strongly associated with OS, PFS, DFS, and ORR. Importantly, patients with detectable residual alterations at completion of prescribed chemotherapy exhibited a markedly shorter DFS, less than that of patients with lower detectable residual alterations, highlighting the potential utility of ctDNA in risk stratification and the value of early trial enrollment for high-risk subgroups.
科研通智能强力驱动
Strongly Powered by AbleSci AI